Ebselen for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Ebselen for COVID-19

2 studies with 56 patients

Serious outcome risk

Ebselen

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Ebselen studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−130%

Mortality (2)−130%

Recovery (2)−17%

RCTs (2)−130%

RCT mortality (2)−130%

Late (2)−130%

00.511.5+

← Ebselen
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of ebselen studies
	Meta-analysis of ebselen studies
Jun 29	Treggiari et al., NCT04483973	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients
	125% higher mortality (p=0.62) and 13% worse recovery (p=0.78). RCT 25 severe COVID-19 patients showing no significant differences with SPI-1005 (ebselen).
Jun 25	Treggiari et al., NCT04484025	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
	141% higher mortality (p=1) and 21% worse recovery (p=0.67). RCT 31 moderate COVID-19 patients showing no significant differences with SPI-1005 (ebselen).